ArticleJCO precision oncology2023

Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.

Mir Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.